Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported):   September 26, 2005

Palatin Technologies, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation) 001-15543 (Commission File Number) 95-4078884 (IRS employer identification number)

4C Cedar Brook Drive, Cranbury, NJ
(Address of principal executive offices) 08512 (Zip Code)

Registrant's telephone number, including area code: (609) 495-2200
Item 3.02 Unregistered Sales of Equity Securities.

On September 26, 2005, we sold 4,499,336 shares of our common stock, and warrants to purchase 719,894 shares of our common stock, in a private placement to King Pharmaceuticals, Inc. for a total purchase price of $10,000,000. No underwriting discounts or commissions were paid. The warrants are exercisable for a three-year period commencing September 26, 2005, at an exercise price of $2.22 per share. King purchased the stock and warrants pursuant to our Collaborative Development and Marketing Agreement with King dated August 12, 2004, and our Securities Purchase Agreement with King, dated August 18, 2004.

We made the sale to King, an accredited investor, pursuant to Regulation D under the Securities Act of 1933. King represented to us that it was purchasing the securities for its own account for investment and not with a view toward resale or distribution to others. The certificates representing the shares of common stock and warrants bear restrictive legends.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PALATIN TECHNOLOGIES, INC.

By: /s/ Stephen T. Wills
Stephen T. Wills, CPA, MST
Executive Vice President - Operations and
Chief Financial Officer

Date: September 30, 2005